7 CRISPR stocks to watch

The best CRISPR stocks depend on your portfolio and investment goals—while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

7 popular CRISPR stocks to watch

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap stocks.

1. Crispr Therapeutics (CRSP)
2. Editas Medicine (EDIT)
3. Regeneron Pharmaceuticals (REGN)
4. Cellectis (CLLS)
5. Beam Therapeutics Inc (BEAM)
6. Bluebird bio (BLUE)
7. Sangamo Therapeutics (SGMO)

Compare investment accounts that help you research stocks

The CRISPR stocks industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering CRISPR stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.

Our picks for platforms with research tools

How to invest in CRISPR stocks

1. Choose an online stock trading platform. Choose from our Top Picks above, use our comparison table below or jump straight to the best stock trading apps in Canada.
2. Sign up for an account. Provide your personal information and sign up.
3. Set up a funding method to pay for the transaction. Deposit funds into your account by linking your banking information.
4. Choose the stocks you want to buy. Search for the stock by name or ticker symbol like CRSP or EDIT.
5. Place your order. Buy the stock. It's that simple.

Learn more about popular CRISPR stocks

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

---

1. Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.

• Previous close price: $32.65
• Market capitalization: $2,800,537,344
• 1 year performance: -52.11%

Buy CRSP stock on Interactive Brokers

---

2. Editas Medicine (EDIT)

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

• Previous close price: $1.03
• Market capitalization: $92,933,464
• 1 year performance: -85.85%

Buy EDIT stock on Interactive Brokers

---

3. Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

• Previous close price: $573.45
• Market capitalization: $62,692,421,632
• 1 year performance: -40.84%
• P/E ratio: 14.9492

Buy REGN stock on Interactive Brokers

---

4. Cellectis (CLLS)

Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates.

• Previous close price: $1.15
• Market capitalization: $164,829,504
• 1 year performance: -54.72%

Buy CLLS stock on Interactive Brokers

---

5. Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

• Previous close price: $15.27
• Market capitalization: $2,217,446,400
• 1 year performance: -53.25%

Buy BEAM stock on Interactive Brokers

---

6. Bluebird bio (BLUE)

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

• Previous close price: $4.95
• Market capitalization: $39,742,832
• 1 year performance: 299.19%

Buy BLUE stock on Interactive Brokers

---

7. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

• Previous close price: $0.66
• Market capitalization: $184,262,192
• 1 year performance: 8.05%

Buy SGMO stock on Interactive Brokers

Buy CRISPR stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Bottom line

While it's possible to turn a profit investing in CRISPR stocks, keep in mind that—like any investment—CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions both in the market and in the gene editing industry, so carefully vet your picks before you invest. If you're new to investing or if it's been a while since you've taken a critical look at your investment accounts, compare brokers to make sure you're getting the best trading features for your needs.

Related: How to buy stocks in Canada

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.